ÆéƼµå Ä¡·áÁ¦ ½ÃÀå : ±â¼ú, ¾àÁ¦ Ŭ·¡½ºº°, Åõ¿© °æ·Î, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, Á¦Á¶ À¯Çüº° - ¼¼°è ¿¹Ãø(2025-2030³â)
Peptide Therapeutics Market by Technology (Hybrid Phase, Liquid Phase, Solid Phase), Drug Class (Adrenocorticotropic Hormone, Calcitonin, Insulin), Route of Administration, Application, End User, Manufacturing Type - Global Forecast 2025-2030
»óǰÄÚµå : 1601173
¸®¼­Ä¡»ç : 360iResearch Private Limited
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 194 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,939 £Ü 5,699,000
PDF, Excel & 1 Year Online Access (Single User License) help
PDF ¹× Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 4,249 £Ü 6,147,000
PDF, Excel & 1 Year Online Access (2-5 User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿Àϱâ¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 5,759 £Ü 8,332,000
PDF, Excel & 1 Year Online Access (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ Áö¿ª »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 6,969 £Ü 10,083,000
PDF, Excel & 1 Year Online Access (Enterprise User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÆéƼµå Ä¡·áÁ¦ ½ÃÀåÀº 2023³â¿¡ 330¾ï 6,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 357¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 8.35%·Î ¼ºÀåÇϰí, 2030³â¿¡´Â 579¾ï 7,000¸¸ ´Þ·¯·Î µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÆéƼµå Ä¡·áÁ¦, »ý¸í °øÇÐ ¹× Á¦¾à ºÎ¹®ÀÇ Áß¿äÇÑ ºÎ¹®¿¡¼­ ³ôÀº ƯÀ̼º, ¾ÈÀü¼º ¹× È¿´ÉÀ¸·Î ÀÎÇØ ÀǾàǰÀ¸·Î ÆéŸÀ̵带 »ç¿ëÇÏ´Â µ¥ ÁßÁ¡À» µÓ´Ï´Ù.ÀÇ ÂªÀº »ç½½·Î ±¸¼ºµÇ¾î ÁÖ·Î Á¾¾çÇÐ, ´ë»ç¼º Áúȯ, °¨¿°Áõ µîÀÇ ºÐ¾ß¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ÇÏ°í ºÎÀÛ¿ëÀÌ Àû°í, Áúȯ °æ·Î¸¦ Á¤È®ÇÏ°Ô Ç¥ÀûÀ¸·Î ÇÏ´Â ´É·ÂÀ¸·ÎºÎÅÍ »ý±â°í ÀÖ½À´Ï´Ù. ±â°ü, Á¦¾àȸ»ç µîÀÔ´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº »ý¹°ÇÐÀûÀ¸·Î Ȱ¼ºÀÎ ÆéƼµåÀÇ ¿¬±¸ È®´ë, ¸¸¼º ÁúȯÀÇ ¸¸¿¬, ÆéƼµå ÇÕ¼º ¹× ¾à¹°Àü´Þ ±â¼úÀÇ Áøº¸ ƯÈ÷ ¸ÂÃãÇü ÀǷᳪ Àç»ý¿ä¹ý¿¡¼­´Â ÆéƼµå°øÇÐÀ̳ª ³ª³ë±â¼úÀÇ Çõ½ÅÀ¸·Î ±âȸ°¡ À;îÁö°í ÀÖ½À´Ï´Ù. ½ÃÀå È®´ë´Â ³ôÀº Á¦Á¶ ºñ¿ë, ÆéŸÀÌµå ¾ÈÁ¤¼º ¹× Àü´Þ º¹À⼺, R&D ÇÁ·Î¼¼½º¸¦ ¹æÇØÇÏ´Â ¾ö°ÝÇÑ ±ÔÁ¦ Àå¾Ö¹° µî ÁÖÁ¦¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °æÀï ±¸µµÀº ¹ÙÀÌ¿À Å×Å©³î·ÎÁöÀÇ Áøº¸ÀÇ ²÷ÀÓ¾ø´Â À¯ÀÔ¿¡ ÀÇÇØ ½ÉÈ­µÇ°í ÀÖÀ¸¸ç, ¹ÎøÇÑ ¿¬±¸ Àü·«ÀÌ ÇÊ¿äÇÕ´Ï´Ù. µÇ°í ÀÖ´Â ºÐ¾ß¿¡´Â ºñÁî´Ï½º ±âȸ°¡ Á¸ÀçÇÕ´Ï´Ù.°í»ó ÆéƼµå ÇÕ¼ºÀÇ °³¹ß µî È­ÇÐ ÇÕ¼ºÀÇ Áøº¸´Â ÇöÀçÀÇ »ý»ê°ú ºñ¿ëÀÇ ÇѰ踦 ±Øº¹ÇÏ´Â ±æÀ» Á¦½ÃÇÕ´Ï´Ù.±â¾÷Àº Á¾ÇÕÀûÀÎ Àü¹® Áö½Ä°ú ÀÚ¿ø °øÀ¯¸¦ Ȱ¿ëÇϱâ À§ÇØ ¿©·¯ ºÎ¼­¿ÍÀÇ ÆÄÆ®³Ê½Ê¿¡ ÁßÁ¡À» µÎ¾î¾ßÇÕ´Ï´Ù. ±×¸®°í Ä¡·á ÆéŸÀ̵åÀÇ ¾ÈÁ¤ ¼º°ú Àü´Þ ¸ÞÄ¿´ÏÁòÀÇ È®´ë¸¦ ¸ñÇ¥·Î ÇÑ ÇöÀç ÁøÇàÁßÀÎ ¿¬±¸°¡ »õ·Î¿î ¼ºÀåÀÇ ±æÀ» ¿­ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. À籸ÃàÀ» ¾à¼ÓÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 330¾ï 6,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 357¾ï 6,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 579¾ï 7,000¸¸ ´Þ·¯
CAGR(%) 8.35%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ÆéƼµå Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

ÆéƼµå Ä¡·áÁ¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ¾ò´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ¿ÏÈ­ÇÒ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ÀÌ´Â Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ´õ¿í ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Porter's Five Forces : ÆéŸÀ̵å Ä¡·áÁ¦ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ ¿öÅ©´Â ÆéŸÀ̵å Ä¡·áÁ¦ ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. Äí´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÇÇÇÒ ¼ö ÀÖÀ¸¸ç ´õ °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸Àå ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÆéƼµå Ä¡·áÁ¦ ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÆéŸÀ̵å Ä¡·áÁ¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÏ¸é ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. À» ¿¹ÃøÇÏ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡µÇ¾î ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ÆéŸÀ̵å Ä¡·áÁ¦ ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

ÆéƼµå Ä¡·áÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¹à°Ô À̸¦ ÅëÇØ ½ÃÀåÀÇ ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í, º¥´õ´Â °æÀïÀÌ °ÝÈ­ÇÏ´Â °¡¿îµ¥ ÀÚ½ÅÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» Çϱâ À§ÇØ ÇÊ¿äÇÕ´Ï´Ù. Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ÆéŸÀ̵å Ä¡·áÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Positioning Matrix´Â ÆéƼµå Ä¡·áÁ¦ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ¿¡ µû¶ó °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀº °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ±¸ºÐÇÏ¿© »ç¿ëÀÚ°¡ Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ½Äº°ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ¾÷°è ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀΰ¡?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

Á¦6Àå ÆéÆ¼µå Ä¡·áÁ¦ ½ÃÀå : ±â¼úº°

Á¦7Àå ÆéÆ¼µå Ä¡·áÁ¦ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°

Á¦8Àå ÆéÆ¼µå Ä¡·áÁ¦ ½ÃÀå : Åõ¿© °æ·Îº°

Á¦9Àå ÆéÆ¼µå Ä¡·áÁ¦ ½ÃÀå : ¿ëµµº°

Á¦10Àå ÆéÆ¼µå Ä¡·áÁ¦ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦11Àå ÆéÆ¼µå Ä¡·áÁ¦ ½ÃÀå : Á¦Á¶ À¯Çüº°

Á¦12Àå ¾Æ¸Þ¸®Ä«ÀÇ ÆéƼµå Ä¡·áÁ¦ ½ÃÀå

Á¦13Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÆéƼµå Ä¡·áÁ¦ ½ÃÀå

Á¦14Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÆéƼµå Ä¡·áÁ¦ ½ÃÀå

Á¦15Àå °æÀï ±¸µµ

±â¾÷ ¸ñ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Peptide Therapeutics Market was valued at USD 33.06 billion in 2023, expected to reach USD 35.76 billion in 2024, and is projected to grow at a CAGR of 8.35%, to USD 57.97 billion by 2030.

Peptide therapeutics, a vital segment within the biotechnology and pharmaceutical sectors, focus on the use of peptides as drugs due to their high specificity, safety, and efficacy. These naturally occurring biological molecules, consisting of short chains of amino acids, cater primarily to areas such as oncology, metabolic disorders, and infectious diseases. The necessity for peptide therapeutics arises from their ability to precisely target disease pathways with fewer side effects compared to traditional small molecule drugs. They find application in drug delivery systems, cancer immunotherapy, and as antimicrobial agents. Key end-users include hospitals, specialized clinics, research institutes, and pharmaceutical companies. Market growth is driven by expanding research into biologically active peptides, escalating prevalence of chronic diseases, and advancements in peptide synthesis and drug delivery technologies. Opportunities are ripe, especially in personalized medicine and regenerative therapies, enhanced by innovations in peptide engineering and nanotechnology. Collaboration between academic research centers and pharmaceutical companies can further uncover novel applications. However, market expansion faces challenges such as high production costs, complexities in peptide stability and delivery, and stringent regulatory hurdles that can impede R&D processes. Additionally, the competitive landscape is intensified by the constant influx of biotechnological advancements, necessitating agile research strategies. Opportunities exist in areas like peptide-based vaccines and diagnostics where demand is burgeoning. Advances in chemical synthesis, such as the development of solid-phase peptide synthesis, present pathways for overcoming current production and cost limitations. Firms should focus on multisector partnerships to leverage comprehensive expertise and resource sharing. The market's dynamic nature underscores the potential for groundbreaking treatments, with ongoing research directed at expanding therapeutic peptides' stability and delivery mechanisms likely to usher in new growth avenues. Exploring these areas for innovation promises to reshape therapeutic approaches in significant ways.

KEY MARKET STATISTICS
Base Year [2023] USD 33.06 billion
Estimated Year [2024] USD 35.76 billion
Forecast Year [2030] USD 57.97 billion
CAGR (%) 8.35%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Peptide Therapeutics Market

The Peptide Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Porter's Five Forces: A Strategic Tool for Navigating the Peptide Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Peptide Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Peptide Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Peptide Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Peptide Therapeutics Market

A detailed market share analysis in the Peptide Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Peptide Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Peptide Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Peptide Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AmbioPharm, Inc., Amgen Inc., Amide Technologies, Inc., AstraZeneca PLC, Bachem Holding AG, Biosynth Ltd., Bristol Myers Squibb Company, Cidara Therapeutics, Inc., Corden Pharma International GmbH, Cybrexa, Inc., Eccogene, Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Ipsen Group, IRBM S.p.A., Ironwood Pharmaceuticals, Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co., Ltd., Peptidream Co., Ltd., Perpetual Medicines Corporation, Pfizer Inc., Piramal Pharma Limited, PolyPeptide Group AG, RELIEF THERAPEUTICS Holding SA, Sanofi S.A., Sanyou Biopharmaceuticals Co., Ltd., Shanghai Full-Life Technologies Co, Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, WuXi AppTec Co., Ltd., and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Peptide Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Peptide Therapeutics Market, by Technology

7. Peptide Therapeutics Market, by Drug Class

8. Peptide Therapeutics Market, by Route of Administration

9. Peptide Therapeutics Market, by Application

10. Peptide Therapeutics Market, by End User

11. Peptide Therapeutics Market, by Manufacturing Type

12. Americas Peptide Therapeutics Market

13. Asia-Pacific Peptide Therapeutics Market

14. Europe, Middle East & Africa Peptide Therapeutics Market

15. Competitive Landscape

Companies Mentioned

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â